NCT00138918 2017-03-03
Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
University of British Columbia
Phase 2 Completed
Clinical Trials
8 trialsNCT01188187 2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3 Completed
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01497470 2016-10-10
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Achieve Life Sciences
Phase 1 Completed
NCT01630733 2016-07-01
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Achieve Life Sciences
Phase 3 Unknown
NCT00327340 2012-10-05
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
Achieve Life Sciences
Phase 2 Completed
NCT00138658 2012-02-06
A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
Achieve Life Sciences
Phase 1/2 Completed